ifosfamide

P3, N=847, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Sep 2025

P2, N=83, Active, not recruiting, Memorial Sloan Kettering Cancer Center

P2, N=100, Not yet recruiting, Fudan University

P2/3, N=210, Recruiting, University of Birmingham | Active, not recruiting --> Recruiting

P2, N=65, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025

On the basis of this case and a comprehensive literature review, we recommend that clinicians consider the possibility of undifferentiated embryonal sarcoma of the liver in patients presenting with non-specific clinical and serological markers, particularly when there is inconsistency between ultrasound and computed tomography imaging findings, along with elevated 18F-fluorodeoxyglucose uptake observed in both the cystic wall and lesion on positron emission tomography-computed tomography examination. Given the rarity and high-grade malignancy of undifferentiated embryonal sarcoma of the liver, heightened clinical awareness and recognition are crucial for early diagnosis and successful therapy.

Despite undergoing radical surgery and receiving systemic treatments including VeIP (vinblastine, ifosfamide, cisplatin), and VDC (vincristine, doxorubicin, cyclophosphamide) regimens, the patient succumbed to death due to disease progression. With the implementation of NGS, we anticipate that more cases with SMARCA4 mutations will be diagnosed in the future. Further research is necessary to unveil therapeutic targets associated for this oncogenic alteration.

The patient was placed on a regimen alternating the combination of vincristine, doxorubicin, and cyclophosphamide for one week and ifosfamide and etoposide for the next. It also discusses the complexity and challenges of managing this rare aggressive malignancy. This case report also addresses the necessity for advanced research into targeted therapies and optimized strategies in the treatment to help improve the survival rates and quality of life for patients with DSRCT.

P3, N=110, Not yet recruiting, Children's Oncology Group

P2, N=78, Active, not recruiting, City of Hope Medical Center | Trial primary completion date: Jan 2025 --> Jan 2024

P1, N=40, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026

P2, N=262, Active, not recruiting, Children's Oncology Group | Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Jun 2024 --> Sep 2024

The study demonstrates that combining E5-siRNA with Oxaliplatin or Ifosfamide enhances the efficacy of chemotherapy in HPV-16 positive cervical cancer cells. This synergistic approach effectively targets multiple aspects of cancer cell behavior, including proliferation, apoptosis, migration, and stemness. The findings suggest that this combination strategy could potentially allow for lower chemotherapy doses, thereby reducing toxicity while maintaining therapeutic efficacy. This research provides valuable insights into targeting HPV E5 as a complementary approach to existing therapies focused on E6 and E7 oncoproteins, opening new avenues for combination therapies in cervical cancer treatment.

P2, N=41, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2024 --> Dec 2024

P=N/A, N=156, Active, not recruiting, Children's Hospitals and Clinics of Minnesota | Trial completion date: Dec 2024 --> Dec 2028 | Trial primary completion date: Dec 2022 --> Dec 2025

P1/2, N=37, Recruiting, Samsung Medical Center

P1/2, N=197, Completed, Grupo Espanol de Investigacion en Sarcomas | Recruiting --> Completed | Trial completion date: Jun 2025 --> Jun 2024 | Trial primary completion date: Jun 2025 --> Jun 2024

P2/3, N=210, Active, not recruiting, University of Birmingham | Not yet recruiting --> Active, not recruiting

P2, N=45, Recruiting, Memorial Sloan Kettering Cancer Center

P2, N=76, Completed, International Extranodal Lymphoma Study Group (IELSG) | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Mar 2024

The association between cell properties and clinical characters of patients provided by our data can act as potential prognostic factors to help physicians to develop effective personalized chemotherapy for osteosarcoma treatments.

In this article, we report a patient with uSRCS who responded to treatment with anti-VEGF inhibitor surufatinib and anti-PD-1 inhibitor camrelizumab after progression on first-line chemotherapy, second-line anlotinib combined with immunotherapy, and third-line chemotherapy...The patient received 4 cycles of the Ifosfamide and epirubicin hydrochloride regimen, and her best objective response was stable disease...Thus, a regimen of gemcitabine plus docetaxel was adopted...As of April 2023, the patient had a progression-free survival time of 26 months. Surufatinib in combination with camrelizumab could be effective in the treatment of advanced uSRCSs.

Renal Ewing's sarcoma with venous tumor embolus is rare in clinic, and it is common in young female patients. The operation is difficult and the prognosis is poor. Surgical resection, adjuvant radiotherapy and chemotherapy can improve the overall survival rate of the patients.

P3; Recruiting --> Active, not recruiting

The different spatial distribution of immune populations and their different association with prognosis support NAC as a modifier of tumour immune infiltrate in STS.

Primary prostate sarcoma is extremely rare and typically has a poor prognosis once diagnosed. Early diagnosis should be based on pathological and immunohistochemical testing results, followed by prompt surgical treatment and adjuvant radiotherapy and chemotherapy. Despite these measures, recurrence is common, underscoring the need for a detailed and appropriate treatment plan and systematic therapy for affected patients.

Decision-making in case of rare histological entities with sparse recommendations in the literature poses a challenge to the treating physician. Treatment strategies should consider oncological safety as well as options of preserving fertility. Gonadotoxic potential of different strategies should be taken into consideration and discussed in detail with the affected patient.

Systemic palliative chemotherapy using the VDC-IE (vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide) regimen was chosen instead of further surgery due to the disease's generalization. The rare character of this disease complicates the diagnostics in clinical practice. Nevertheless, rare sarcomas should be considered in patients with non-specific abdominal symptoms, including patients with incarcerated ventral hernia.

P2, N=89, Recruiting, Institute of Hematology & Blood Diseases Hospital, China

P2, N=92, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025

Despite advances in our understanding of the genetics and molecular biology of MPNST, further research is warranted to: (1) unravel the complex pathogenesis of this condition; (2) improve diagnostic yield; (3) delineate the appropriate roles of chemotherapy and radiation; and (4) develop a targeted therapy (or combination of such treatments) that is well tolerated and prolongs survival.

P1/2, N=30, Active, not recruiting, Academic and Community Cancer Research United | N=63 --> 30

P1/2, N=56, Active, not recruiting, Antengene Corporation | Terminated --> Active, not recruiting | Trial completion date: May 2024 --> Dec 2024 | Trial primary completion date: May 2024 --> Dec 2024

P2, N=60, Recruiting, Chinese PLA General Hospital | Not yet recruiting --> Recruiting

P3, N=200, Recruiting, Institute of Cancer Research, United Kingdom | Trial completion date: May 2026 --> Nov 2027 | Trial primary completion date: May 2024 --> May 2025

P1/2, N=307, Completed, Kite, A Gilead Company | Trial primary completion date: Sep 2020 --> Jul 2023

P2, N=34, Active, not recruiting, Seoul National University Hospital | Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> May 2025 | Trial primary completion date: Dec 2021 --> Aug 2023

P1/2, N=56, Terminated, Antengene Corporation | N=97 --> 56 | Trial completion date: Dec 2024 --> May 2024 | Recruiting --> Terminated; Based on the adjustment of clinical research and development strategy，sponsor decided to terminate the study

P2, N=25, Not yet recruiting, Sun Yat-sen University

P2, N=44, Suspended, Peking University People's Hospital | Trial completion date: Apr 2024 --> Apr 2026 | Recruiting --> Suspended | Trial primary completion date: Apr 2023 --> Apr 2026

P2, N=81, Completed, Peking University People's Hospital | Recruiting --> Completed

Our findings support the use of PD-1 blockade in HIV-cHL for the same indications as the general population with cHL.